A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Tonogenchoncel-L (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Kolon TissueGene
- 16 Mar 2018 According to a Kolon TissueGene media release, TissueGene changed its name to Kolon TissueGene.
- 26 Jun 2017 Status changed from planning to not yet recruiting.
- 01 Nov 2016 According to a TissueGene media release, received a Special Protocol Assessment designation for this trial. Company anticipated to initiate this trial in the second quarter of 2017.